Home » Genzyme Presents Second Phase III Study of Once-daily Oral Aubagio
Genzyme Presents Second Phase III Study of Once-daily Oral Aubagio
Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Yahoo! Finanace
Yahoo! Finanace
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May